Patient characteristics and outcome on Protocol 95-01
| . | Total . | 5-y EFS ± SE . | P . |
|---|---|---|---|
| All patients | 491 | 82 ± 2 | — |
| DFCI risk group | .01 | ||
| Standard | 272 | 86 ± 2 | |
| High | 219 | 76 ± 3 | |
| NCI risk group, non-infants* | .19 | ||
| Good-risk pre-B | 299 | 86 ± 2 | |
| Poor-risk pre-B | 121 | 70 ± 4 | |
| Good-risk T | 12 | 83 ± 11 | |
| Poor-risk T | 40 | 85 ± 6 | |
| Age | <.01 | ||
| Younger than 1.00 y | 14 | 42 ± 13 | |
| 1.00-9.99 y | 385 | 84 ± 2 | |
| 10.00-18.00 y | 92 | 75 ± 5 | |
| WBC count | <.01 | ||
| Less than 20.000 × 109/L | 318 | 87 ± 2 | |
| 20.000-49.999 × 109/L | 76 | 71 ± 5 | |
| 50.000-99.999 × 109/L | 43 | 79 ± 6 | |
| 100.000 × 109/L or higher | 54 | 66 ± 7 | |
| Sex | .26 | ||
| Male | 274 | 79 ± 3 | |
| Female | 217 | 84 ± 3 | |
| Immunophenotype | .57 | ||
| B-lineage | 434 | 81 ± 2 | |
| T-cell | 52 | 85 ± 5 | |
| CNS at diagnosis | .16 | ||
| CNS-1 | 403 | 83 ± 2 | |
| CNS-2 | 49 | 72 ± 7 | |
| CNS-3 | 12 | 75 ± 13 | |
| Traumatic | 19 | 68 ± 11 | |
| Down syndrome | .33 | ||
| No | 477 | 82 ± 2 | |
| Yes | 14 | 71 ± 12 | |
| Ploidy in 309 assessable patients | .12 | ||
| Hyperdiploid 50 or greater | 82 | 86 ± 4 | |
| Hyperdiploid less than 50 | 23 | 73 ± 9 | |
| Diploid | 134 | 84.3 | |
| Pseudodiploid | 54 | 71 ± 6 | |
| Hypodiploid | 16 | 73 ± 12 |
| . | Total . | 5-y EFS ± SE . | P . |
|---|---|---|---|
| All patients | 491 | 82 ± 2 | — |
| DFCI risk group | .01 | ||
| Standard | 272 | 86 ± 2 | |
| High | 219 | 76 ± 3 | |
| NCI risk group, non-infants* | .19 | ||
| Good-risk pre-B | 299 | 86 ± 2 | |
| Poor-risk pre-B | 121 | 70 ± 4 | |
| Good-risk T | 12 | 83 ± 11 | |
| Poor-risk T | 40 | 85 ± 6 | |
| Age | <.01 | ||
| Younger than 1.00 y | 14 | 42 ± 13 | |
| 1.00-9.99 y | 385 | 84 ± 2 | |
| 10.00-18.00 y | 92 | 75 ± 5 | |
| WBC count | <.01 | ||
| Less than 20.000 × 109/L | 318 | 87 ± 2 | |
| 20.000-49.999 × 109/L | 76 | 71 ± 5 | |
| 50.000-99.999 × 109/L | 43 | 79 ± 6 | |
| 100.000 × 109/L or higher | 54 | 66 ± 7 | |
| Sex | .26 | ||
| Male | 274 | 79 ± 3 | |
| Female | 217 | 84 ± 3 | |
| Immunophenotype | .57 | ||
| B-lineage | 434 | 81 ± 2 | |
| T-cell | 52 | 85 ± 5 | |
| CNS at diagnosis | .16 | ||
| CNS-1 | 403 | 83 ± 2 | |
| CNS-2 | 49 | 72 ± 7 | |
| CNS-3 | 12 | 75 ± 13 | |
| Traumatic | 19 | 68 ± 11 | |
| Down syndrome | .33 | ||
| No | 477 | 82 ± 2 | |
| Yes | 14 | 71 ± 12 | |
| Ploidy in 309 assessable patients | .12 | ||
| Hyperdiploid 50 or greater | 82 | 86 ± 4 | |
| Hyperdiploid less than 50 | 23 | 73 ± 9 | |
| Diploid | 134 | 84.3 | |
| Pseudodiploid | 54 | 71 ± 6 | |
| Hypodiploid | 16 | 73 ± 12 |
NCI age/WBC criteria11 used to define good-risk group (children 1 to <10 yr old with a leukocyte count <50 × 109/L) and poor risk group (all others) for both B-precursor and T-cell patients.